ClinicalTrials.gg
CompletedNCT03764293Updated Feb 6, 2024Results posted

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

A Phase 3 interventional study of SHR-1210 and Apatinib in Locally Advanced or Metastatic and Unresectable HCC, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 121 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
543
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
47th of 401
543 · median 90
Started
2019
with 25 others
Phase 3
75 of 485
21 open now
Registered
122nd of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 47th largest by enrollment of the 401 interventional ones that give a count, is one of 26 that started in 2019, is one of 75 in phase 3, and was the 122nd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.

03

Conditions studied

  • Locally Advanced or Metastatic and Unresectable HCC

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically or confirmed advanced HCC
  • No previous systematic treatment for HCC
  • Have at least one (in accordance with v1.1)
  • BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy
  • -PS score 0 or 1
  • Class: Grade A
  • of at least 12 weeks
  • Subjects with infection: HBV DNA\<500 IU/ml or \< 2500 copy/mL, and have received anti-HBV therapy for at least 14 days prior to enrollment in the study
  • Subjects with (+) must receive antiviral therapy
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously
  • Moderate-to-severe ascites with clinical symptoms
  • History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
  • Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
  • Known genetic or acquired hemorrhage or thrombotic tendency
  • Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
  • Cardiac clinical symptom or disease that is not well controlled
  • Hypertension that can not be well controlled through antihypertensive drugs
  • Factors to affect oral administration
  • History of hepatic encephalopathy
  • Previous or current presence of to central nervous system
  • infection
  • Combined and co-infection
  • Be ready for or previously received organ or allogenic bone marrow transplantation
  • Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity
  • Active known, or suspected disease
  • Subjects with a condition requiring systemic treatment with either or other medications within 14 days of first administration of study treatment
  • Use of potent inducers or inhibitors within 2 weeks prior to the signature of ICF
  • Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug
  • Severe infection within 4 weeks prior to the start of study treatment
  • Palliative radiotherapy for non-target lesions to control symptoms is allowed, but it must be completed at least 2 weeks prior to the start of study treatment
  • Treatment of other product(s) within 28 days prior to the start of study treatment
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
543 participants (actual)

Study arms

  • Experimental
    SHR-1210

    SHR-1210+Apatinib

    Drug: SHR-1210 · Drug: Apatinib

  • Active comparator
    Control

    Sorafenib

    Drug: Sorafenib

Interventions

  • Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial

    Also known as: Camrelizumab

  • Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet

    Also known as: Rivoceranib

  • Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause.

    Time frame: Up to approximately 3 years

  2. Progression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.1

    PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) by tumor image evaluation or death from any cause whichever occurs first as determined by BIRC according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions and the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm), or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR defined as the percentage of subjects with complete response (CR) or partial response (PR) evaluated by the BIRC or investigator based on RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Overall Response (OR)=CR+PR.

    Time frame: Up to approximately 3 years

  2. Disease Control Rate (DCR)

    DCR defined as the percentage of subjects with complete response, partial response or stable disease (SD) ≥ 8 weeks evaluated by the BIRC or investigator based on RECIST v1.1. Complete response (CR) was defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to approximately 3 years

  3. Duration of Response (DOR)

    DOR defined as time from the date of first record of objective response (CR or PR) to the first occurrence of radiological progression or death, whichever comes first, evaluated by the BIRC or investigator based on RECIST v1.1. Complete response (CR) was defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 3 years

07

Results

Posted Feb 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneCamrelizumab+Rivoceranib ArmSorafenib Arm
Started272271
Treated272269
Completed230249
Not completed4222

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death from any cause.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Overall Survival (OS)
monthsCamrelizumab+Rivoceranib ArmSorafenib Arm
Overall Survival (OS)22.1 (19.1 to 27.2)15.2 (13.0 to 18.5)
PrimaryProgression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.1

PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) by tumor image evaluation or death from any cause whichever occurs first as determined by BIRC according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions and the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm), or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Progression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.1
monthsCamrelizumab+Rivoceranib ArmSorafenib Arm
Progression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.15.6 (5.5 to 7.4)3.7 (3.1 to 3.7)
SecondaryObjective Response Rate (ORR)

ORR defined as the percentage of subjects with complete response (CR) or partial response (PR) evaluated by the BIRC or investigator based on RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Overall Response (OR)=CR+PR.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCamrelizumab+Rivoceranib ArmSorafenib Arm
Objective Response Rate (ORR)25 (20 to 31)6 (3 to 9)
SecondaryDisease Control Rate (DCR)

DCR defined as the percentage of subjects with complete response, partial response or stable disease (SD) ≥ 8 weeks evaluated by the BIRC or investigator based on RECIST v1.1. Complete response (CR) was defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCamrelizumab+Rivoceranib ArmSorafenib Arm
Disease Control Rate (DCR)78 (73 to 83)54 (48 to 60)
SecondaryDuration of Response (DOR)

DOR defined as time from the date of first record of objective response (CR or PR) to the first occurrence of radiological progression or death, whichever comes first, evaluated by the BIRC or investigator based on RECIST v1.1. Complete response (CR) was defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Duration of Response (DOR)
monthsCamrelizumab+Rivoceranib ArmSorafenib Arm
Duration of Response (DOR)14.8 (8.4 to NA)9.2 (5.3 to NA)

Adverse events

Collected over Up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Camrelizumab+Rivoceranib Arm34/272 (12.5%)114/272 (41.9%)268/272 (98.5%)
Sorafenib Arm17/269 (6.3%)49/269 (18.2%)262/269 (97.4%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventCamrelizumab+Rivoceranib ArmSorafenib Arm
Upper gastrointestinal haemorrhageGastrointestinal disorders12/2721/269
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/2722/269
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/2724/269
Aspartate aminotransferase increasedInvestigations10/2722/269
Hepatic encephalopathyNervous system disorders10/2720/269
Alanine aminotransferase increasedInvestigations8/2721/269
Blood bilirubin increasedInvestigations8/2722/269
Platelet count decreasedInvestigations5/2720/269
Abdominal painGastrointestinal disorders4/2724/269
AscitesGastrointestinal disorders4/2720/269
Most frequent other events
Showing 10 of 62
Most frequent other events
EventCamrelizumab+Rivoceranib ArmSorafenib Arm
HypertensionVascular disorders190/272118/269
Aspartate aminotransferase increasedInvestigations178/272137/269
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders101/272163/269
Alanine aminotransferase increasedInvestigations154/272115/269
Platelet count decreasedInvestigations138/272105/269
ProteinuriaRenal and urinary disorders136/27282/269
Blood bilirubin increasedInvestigations131/272112/269
DiarrhoeaGastrointestinal disorders90/272114/269
Gamma-glutamyltransferase increasedInvestigations88/27280/269
HypoalbuminaemiaMetabolism and nutrition disorders84/27262/269

Baseline characteristics

Age, Customized
Age, Customized(participants)Camrelizumab+Rivoceranib ArmSorafenib ArmTotal
<65 Years191210401
>=65 Years8161142
Sex: Female, Male
Sex: Female, Male(Participants)Camrelizumab+Rivoceranib ArmSorafenib ArmTotal
Female454186
Male227230457
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Camrelizumab+Rivoceranib ArmSorafenib ArmTotal
Asian226224450
Black Or African American101
White444690
Other112
08

Study locations

121 sites
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • University of California San Diego (UCSD)-Moores Cancer Center
    La Jolla, California 92037, United States
  • University of California - Irvine
    Orange, California 92868, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Cornell University Weill Cornell Medical College
    New York, New York 10065, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Renovatio Clinical
    The Woodlands, Texas 77380, United States
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • UZA
    Edegem, 2650, Belgium
  • AZ Maria Middelares
    Gent, 9000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • Anhui Provincal Cancer Hospital
    Hefei, Anhui 230000, China
  • Anhui Provincal Hospital
    Hefei, Anhui 230000, China
  • The First Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui 230009, China
  • The Second Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui 230601, China
  • Chinese Academy of Medical Sciences Cancer Hospital
    Beijing, Beijing 100020, China
  • Beijing cancer Hospital
    Beijing, Beijing 100089, China
  • Peking University International Hospital
    Beijing, Beijing 102206, China
  • The Second Hospital Affiliated To AMU
    Chongqing, Chongqing 400037, China
  • The First Hospital Affiliated To AMU
    Chongqing, Chongqing 400038, China
  • TheThird Affiliated Hospital ,Army Medical University
    Chongqing, Chongqing 400042, China
  • The Second Affiliated Hospital of ChongQing Medical University
    Chongqing, Chongqing 400060, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The 940th Hospital of the joint logistic support force of People's Liberation Army
    Lanzhou, Gansu, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510220, China
  • NanFang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The first affiliated hospital of guangxi medical university
    Nanning, Guangxi 530021, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Wuhan Union Hospital,Tongji Medical College,Huazhong University of Science&Technology
    Wuhan, Hubei 430022, China
  • Tongji hospital,Tongji Medical College,Huazhong University of Science&Technology
    Wuhan, Hubei 430030, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
  • Eastern Theater General Hospital, Qinhuai District Medical Area
    Nanjing, Jiangsu 210002, China
  • The First Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The Sixth People's Hospital of Shengyang
    Shengyang, Liaoning 110006, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital Affiliated to Shandong University
    Jinan, Shandong 250000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai 200043, China
  • West China Hospital of Sichuan University
    Chengdu, Si Chuan 610041, China
  • Sichuan Cancer Hospital&Institute
    Chengdu, Sichuan 610054, China
  • Sir Run Run Shaw Hospital
    Hangzhou, Zhejiang 310016, China
  • ZheJiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang, China
  • Charite Universitaetsmedizin Berlin - Campus Virchow-Klinikum Berlin
    Berlin, 13353, Germany
  • Pamela Youde Nethersole Eastern Hospital
    Hong Kong, Hong Kong
  • The University of Hong Kong
    Hong Kong, Hong Kong
  • Tuen Mun Hospital
    Hong Kong, Hong Kong
  • The Chinese University of Hong Kong
    Shatin, Hong Kong
  • A.S.L. Napoli 1 Centro Ospedale del Mare
    Ponticelli, Napoli 80147, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, 40138, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
    Brescia, 25123, Italy
  • Azienda Ospedaliero-Universitaria
    Cagliari, 09124, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50134, Italy
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
    Verona, 37134, Italy
  • Seoul National University Bundang Hospital Gyeonggi-do
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon-si, Gyeonggi-do 16247, Korea, Republic of
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, Korea, Republic of
  • Dong-A University Hospital
    Busan, 602715, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02481, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Centrum Medyczne Pratia Gdynia
    Gdynia, 81338, Poland
  • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
    Gliwice, 44101, Poland
  • Pratia MCM Krakow
    Krakow, 30510, Poland
  • Przychodnia Med-Polonia Sp. z o.o.
    Poznan, 60693, Poland
  • Wielkopolskie Centrum Onkologii
    Poznan, 61866, Poland
  • Centrum Zdrowia MDM
    Warszawa, 00635, Poland
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
    Warszawa, 02034, Poland
  • NZOZ Centrum Badan Klinicznych
    Wroclaw, 51162, Poland
  • SBIH of Arkhangelsk region "Arkhangelsk Clinical Oncological Dispensary"
    Arkhangelsk, 164045, Russian Federation
  • SBHI Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine
    Chelyabinsk, 454087, Russian Federation
  • Irkutsk Regional Oncology Dispensary
    Irkutsk, 664035, Russian Federation
  • SBIH " Clinical Oncological Dispensary # 1"
    Krasnodar, 350040, Russian Federation
  • RBIH "Kursk regional clinical oncology dispensary" of Kursk Region Healthcare Committee
    Kursk, 305035, Russian Federation
  • "VitaMed" LLC
    Moscow, 121309, Russian Federation
  • SBIH of Moscow city "Moscow city oncology hospital №62" of Moscow Healthcare departement
    Moscow, 143423, Russian Federation
  • CJSC Avicenna
    Novosibirsk, 630099, Russian Federation
  • BHI of Omsk region "Clinical Oncology Dispensary"
    Omsk, 644013, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    Saint-Petersburg, 197022, Russian Federation
  • SPb SBIH "City Clinical Oncological Dispensary"
    Saint-Petersburg, 197022, Russian Federation
  • FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
    Saint-Petersburg, 197758, Russian Federation
  • SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan
    Ufa, 450054, Russian Federation
  • Hospital Universitario Reina Sofia
    Cordoba, Córdoba 14004, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario HM Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Changhua Christian Medical Foundation Changhua Christian Hospital
    Changhua, 500006, Taiwan

Showing the first 100 of 121 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2022, 31 months.

Results were first posted in Feb 2024, 1 year 11 months after primary completion.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 31 months is below that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2018
First posted
Dec 5, 2018
StartActual
Jun 10, 2019
Primary completionActual
Feb 8, 2022
CompletionActual
Jun 14, 2023
Results first posted
Feb 6, 2024
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03764293
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Jun 10, 2019
Primary completion
Feb 8, 2022
Completion
Jun 14, 2023
Results posted
Feb 6, 2024
Last update
Feb 6, 2024

Study contacts

Shukui Qin, MD
principal investigator · Eastern Theater General Hospital,QinHuai District Medical Area

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion